Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2025-09-03 00:00:00 ET · period of report 2025-08-28 · accession 0000950170-25-112661 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-03 | 2025-08-28 | SPRO | Mahadevia Ankit | Dir | S - Sale | $1.97 | -6,572 | 703.3K | -0.9% | -$12.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-28 | S | D | 6,572 | $1.97 | 703,294 | D | — | — | (F1) The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021. (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. |